Contravir Pharmaceuticals Inc., of Edison, N.J., said tenofovir exalidex (TXL, formerly called CMX157), the company's prodrug analog of tenofovir, exhibited increased antiviral activity at the highest planned dose of 100 mg in the ongoing phase IIa multiple ascending-dose trial in patients with hepatitis B virus.